Carmot Therapeutics

Carmot Therapeutics applies its proprietary technology, Chemotype Evolution, to address unmet chemical needs in drug discovery, focusing on high-profile targets for which drug leads have been difficult to identify. Founded in 2008 by Drs. Stig K. Hansen and Daniel A. Erlanson, Carmot has built and optimized this powerful platform to rapidly and efficiently unlock therapeutic target space not currently accessible to conventional small molecule technologies. Carmot is currently using Chemotype Evolution to discover novel drug candidates targeting validated pathways in metabolic disease, oncology and inflammation.

Management

Stig K. Hansen, PhD, Chief Executive Officer

Daniel A. Erlanson, PhD, President

Board of Directors

Stig K. Hansen, PhD, Chief Executive Officer

Daniel A. Erlanson, PhD, President

David V. Goeddel, PhD, Managing Partner, The Column Group

Tim Kutzkey, PhD, Partner, The Column Group

Scientific Advisory Board

Professor John Kuryian, PhD, University of California Berkeley and Howard Hughes Medical Institute

Robert McDowell, PhD, Vice President of Research, 3-V Therapeutics